ClinicalTrials.gg
RecruitingNCT07650201Updated Nov 13, 2026

Trial to Investigate the Safety and Effectiveness of the KI-362-US1 (YP2.2VM) Intraocular Lens (IOL) in Adult Participants for Correction of Aphakia Following Cataract Extraction

An interventional study of KI-362-US1 (YP2.2VM) in Aphakia, Postcataract, sponsored by Kowa Research Institute, Inc.. Recruiting at 9 sites in United States. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Kowa Research Institute, Inc. (part of Kowa Company, Ltd.) · Not applicable, Interventional, and Treatment

Updated Nov 13, 2026Now RecruitingFirst site in United States+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
340
Allocation
Not applicable
Ages
22 Years and older
Sex
All
01

Study summary

This study is designed to evaluate how well an artificial lens, called an intraocular lens (IOL), performs in adults undergoing cataract surgery. During cataract surgery, the eye's natural lens is removed and replaced with an artificial lens to improve vision.

The main goal of the study is to evaluate participants' vision after the IOL is placed in the eye. Approximately one year after surgery, participants' vision will be assessed to determine how clearly they can see.

The results of this study will provide additional information about the performance of the IOL in adults undergoing cataract surgery.

02

Conditions studied

  • Aphakia, Postcataract
03

In context

Lead sponsor

Kowa Research Institute, Inc. is the lead sponsor of 47 studies on the registry; 1 is open to participants now.

Of its 20 completed or terminated interventional studies of FDA-regulated products, 9 (45%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
22 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are able and willing to provide written , attend all scheduled visits, and comply with all trial procedures and follow-up
  • Have a study eye with visually significant cataract for which phacoemulsification cataract extraction and posterior chamber IOL implantation is indicated
  • Meet all other inclusion criteria outlined in the clinical study protocol

Exclusion criteria

Exclusion Criteria:

  • Have serious systemic disease that could increase operative risk or conditions that can confound the surgical outcome
  • Within 30 days of the Screening Visit, use of systemic medications with significant ocular side effects or any medications that could confound the outcome or increase participant risk
  • Meet any other exclusion criteria outlined in the clinical study protocol
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
340 participants (estimated)

Study arms

  • Experimental
    KI-362-US1

    Participants receive an intraocular lens (IOL) implanted during cataract surgery to replace the natural lens of the eye. The IOL is delivered using a single-use, preloaded delivery device and positioned within the eye's natural lens capsule.

    Device: KI-362-US1 (YP2.2VM)

Interventions

  • DeviceKI-362-US1 (YP2.2VM)

    Injector and one-piece (1P) monofocal IOL

06

What researchers measure

Primary outcomes

  1. Proportion of Participants Achieving a Predefined BCDVA Criterion at Visit 5

    Proportion of participants achieving a predefined best-corrected distance visual acuity (BCDVA) criterion, as measured using Early Treatment Diabetic Retinopathy Study (ETDRS) illuminated charts at postoperative days 330-390 (Visit 5, Form 5).

    Time frame: Baseline through Visit 5, approximately Days 330-390.

  2. Proportion of Participants With Selected Ocular Adverse Events

    Proportion of participants experiencing one or more predefined ocular adverse events following treatment, including both cumulative and persistent events. Events are assessed based on their occurrence or persistence during the study period.

    Time frame: Baseline through end of study (up to 15 months)

07

Study locations

9 of 9 sites recruiting
  • Beverly Hills Institute of Ophthalmology
    Beverly Hills, California 90210, United States
    Recruiting
  • Icon EyeCare
    Grand Junction, Colorado 81501, United States
    Recruiting
  • North Georgia Eye Associates
    Gainesville, Georgia 30501, United States
    Recruiting
  • Ophthalmology Consultants Ltd
    St Louis, Missouri 63128, United States
    Recruiting
  • Carolina Eyecare Physicians
    Mt. Pleasant, South Carolina 29464, United States
    Recruiting
  • Houston Eye Associates, North Loop
    Houston, Texas 77008, United States
    Recruiting
  • Berkeley Eye
    Houston, Texas 77027, United States
    Recruiting
  • Texas Eye Research
    Hurst, Texas 76054, United States
    Recruiting
  • Piedmont Eye Center
    Lynchburg, Virginia 24502, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Oct 2026 (actual). Primary completion is estimated for Sep 2027, 11 months after the start.

Start moved twice since we started tracking on Sep 25, 2026: Aug 2026 → Oct 2026, last on Nov 13, 2026.

Primary completion moved once since we started tracking on Sep 25, 2026: Nov 2028 → Sep 2027, on Nov 6, 2026.

Completion moved once since we started tracking on Sep 25, 2026: Nov 2028 → Sep 2028, on Nov 6, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2026
First posted
Jun 16, 2026
StartActual
Oct 30, 2026was Aug 2026
Primary completionEst.
Sep 2027was Nov 2028
CompletionEst.
Sep 2028was Nov 2028
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 13, 2026
Sites
9 sites added — first site in United States. 9 sites changed recruiting status (9 now recruiting)
Show 9 sites
  • Beverly Hills Institute of Ophthalmology · Beverly Hills, United Statesno status→Recruiting
  • Icon EyeCare · Grand Junction, United Statesno status→Recruiting
  • North Georgia Eye Associates · Gainesville, United Statesno status→Recruiting
  • Ophthalmology Consultants Ltd · St Louis, United Statesno status→Recruiting
  • Carolina Eyecare Physicians · Mt. Pleasant, United Statesno status→Recruiting
  • Houston Eye Associates, North Loop · Houston, United Statesno status→Recruiting
  • Berkeley Eye · Houston, United Statesno status→Recruiting
  • Texas Eye Research · Hurst, United Statesno status→Recruiting
  • Piedmont Eye Center · Lynchburg, United Statesno status→Recruiting
Show 9 added (9 United States)
  • Beverly Hills Institute of Ophthalmology · Beverly Hills, United States
  • Icon EyeCare · Grand Junction, United States
  • North Georgia Eye Associates · Gainesville, United States
  • Ophthalmology Consultants Ltd · St Louis, United States
  • Carolina Eyecare Physicians · Mt. Pleasant, United States
  • Houston Eye Associates, North Loop · Houston, United States
  • Berkeley Eye · Houston, United States
  • Texas Eye Research · Hurst, United States
  • Piedmont Eye Center · Lynchburg, United States
across 2 updates, Nov 6, 2026 – Nov 13, 2026
Start date
Aug 2026→Oct 30, 2026 (actual)
moved 2 times, Nov 6, 2026 – Nov 13, 2026
Primary completion
Nov 2028→Sep 2027
Nov 6, 2026
Study completion
Nov 2028→Sep 2028
Nov 6, 2026
Primary outcomes
2 edited
What changed in the outcomes
  • EditedProportion of Participants with Incidence ofWith Selected Ocular Adverse EventsTime frame: Baseline through end of study (up to 15 months)
  • ChangedBefore Proportion of Participants whose BCDVA Achieved 0.30 logMAR or Better at Form 5Now Proportion of Participants Achieving a Predefined BCDVA Criterion at Visit 5Time frame: Baseline (Form 0) through Visit 5 (Form 5), approximately Days 330-390 → Baseline through Visit 5, approximately Days 330-390.
Nov 6, 2026
Secondary outcomes
4 removed
What changed in the outcomes
  • RemovedProportion of Participants with Lens Axis Misalignment of <10 degrees From Baseline to Form 4Time frame: Baseline (Form 0) through Visit 4 (Form 4), approximately Days 120-180
  • RemovedProportion of Participants with Lens Axis Misalignment of <10 degrees From Baseline to Form 5Time frame: Baseline (Form 0) through Visit 5 (Form 5), approximately Days 330-390
  • RemovedProportion of Participants with Lens Axis Misalignment of <20 degrees From Baseline to Form 4Time frame: Baseline (Form 0) through Visit 4 (Form 4), approximately Days 120-180
  • RemovedProportion of Participants with Lens Axis Misalignment of <20 degrees From Baseline to Form 5Time frame: Baseline (Form 0) through Visit 5 (Form 5), approximately Days 330-390
Nov 6, 2026
Show all 2 updates
  1. Nov 13, 2026
    Not yet recruiting→Recruiting
    9 sites changed recruiting status (9 now recruiting)
    Show 9 sites
    • Beverly Hills Institute of Ophthalmology · Beverly Hills, United Statesno status→Recruiting
    • Icon EyeCare · Grand Junction, United Statesno status→Recruiting
    • North Georgia Eye Associates · Gainesville, United Statesno status→Recruiting
    • Ophthalmology Consultants Ltd · St Louis, United Statesno status→Recruiting
    • Carolina Eyecare Physicians · Mt. Pleasant, United Statesno status→Recruiting
    • Houston Eye Associates, North Loop · Houston, United Statesno status→Recruiting
    • Berkeley Eye · Houston, United Statesno status→Recruiting
    • Texas Eye Research · Hurst, United Statesno status→Recruiting
    • Piedmont Eye Center · Lynchburg, United Statesno status→Recruiting
    Start date Nov 2026→Oct 30, 2026 (now actual)
  2. Nov 6, 2026
    9 sites added — first site in United States
    Show 9 added (9 United States)
    • Beverly Hills Institute of Ophthalmology · Beverly Hills, United States
    • Icon EyeCare · Grand Junction, United States
    • North Georgia Eye Associates · Gainesville, United States
    • Ophthalmology Consultants Ltd · St Louis, United States
    • Carolina Eyecare Physicians · Mt. Pleasant, United States
    • Houston Eye Associates, North Loop · Houston, United States
    • Berkeley Eye · Houston, United States
    • Texas Eye Research · Hurst, United States
    • Piedmont Eye Center · Lynchburg, United States
    Start date Aug 2026→Nov 2026
    Primary completion Nov 2028→Sep 2027
    Study completion Nov 2028→Sep 2028
    Primary outcomes 2 edited
    What changed in the outcomes
    • EditedProportion of Participants with Incidence ofWith Selected Ocular Adverse EventsTime frame: Baseline through end of study (up to 15 months)
    • ChangedBefore Proportion of Participants whose BCDVA Achieved 0.30 logMAR or Better at Form 5Now Proportion of Participants Achieving a Predefined BCDVA Criterion at Visit 5Time frame: Baseline (Form 0) through Visit 5 (Form 5), approximately Days 330-390 → Baseline through Visit 5, approximately Days 330-390.
    Secondary outcomes 4 removed
    What changed in the outcomes
    • RemovedProportion of Participants with Lens Axis Misalignment of <10 degrees From Baseline to Form 4Time frame: Baseline (Form 0) through Visit 4 (Form 4), approximately Days 120-180
    • RemovedProportion of Participants with Lens Axis Misalignment of <10 degrees From Baseline to Form 5Time frame: Baseline (Form 0) through Visit 5 (Form 5), approximately Days 330-390
    • RemovedProportion of Participants with Lens Axis Misalignment of <20 degrees From Baseline to Form 4Time frame: Baseline (Form 0) through Visit 4 (Form 4), approximately Days 120-180
    • RemovedProportion of Participants with Lens Axis Misalignment of <20 degrees From Baseline to Form 5Time frame: Baseline (Form 0) through Visit 5 (Form 5), approximately Days 330-390
    + 3 other changes: verification date, description and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07650201
Responsible party
Sponsor
First posted
Jun 16, 2026
Start date
Oct 30, 2026
Primary completion
Sep 2027 (estimated)
Completion
Sep 2028 (estimated)
Last update
Nov 13, 2026

Study contacts

Director, Clinical Operations
Contact
Clinical@KowaUS.com
919-433-1600
Shona Pendse, MD, MMSc
study chair · Kowa Research Institute, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion